Company profile

Ticker
ALIM
Exchange
CEO
Richard S. Eiswirth
Employees
Incorporated in
Location
Fiscal year end
SEC CIK

ALIM stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Nov 19
11 Dec 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 12.85M 10.86M 12.89M 15.49M
Net income -3.14M -5.04M -2.76M -1.25M
Diluted EPS -0.04 -0.07 -0.04 -0.01
Net profit margin -24.44% -46.41% -21.44% -8.06%
Operating income -1.72M -3.59M -1.4M 72K
Net change in cash -4.25M -937K 51K 452K
Cash on hand 7.9M 12.16M 13.09M 13.04M
Cost of revenue
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 46.97M 35.91M 34.33M 22.44M
Net income -16.38M -22M -33.17M -30.65M
Diluted EPS 0.25 -0.33 -0.63 -0.69
Net profit margin -34.88% -61.26% -96.62% -137%
Operating income -9.67M -16.45M -27.85M -39M
Net change in cash -11.02M -6.91M -96K -45.62M
Cash on hand 13.04M 24.07M 30.98M 31.08M
Cost of revenue 3.44M 2.34M 1.76M

Financial data from company earnings reports

Financial report summary

?
Management Discussion
  • ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Alimera Sciences, Inc., and its subsidiaries (we, our, Alimera or the Company), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We presently focus on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.
  • Our only product is ILUVIEN®, which has received marketing authorization in the U.S., Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Kuwait, Lebanon, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, the United Arab Emirates and the United Kingdom. In the U.S., Australia, Canada, Kuwait, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accurate, Arzneimittel, Bundesinstitut, confidence, Department, harm, imposed, investor, Lincoln, lived, medium, Medizinprodukte, OTC, Panel, Park, pilot, preliminary, proposal, proposed, quotation, ratio, real, recruit, refilling, removed, resubmission, setup, split, stockholder, und, undiscounted, vacant, visibility, volatility
Removed: commercially